Heterocyclic-substituted tricyclics of the formula ##STR1##

or a pharmaceutically acceptable salts thereof, wherein:

    • n1 and n2 are independently 0-2;
    • Het is an optionally substituted mono-, bi- or tricyclic heteroaromatic group;
    • B is alkyl or optionally substituted alkenyl;
    • R22 is —COR23 or a carboxy, sulfinyl, sulfonyl, sulfonamide or amino acid derivative;
    • R23 is haloalkyl; alkenyl; haloalkenyl; alkynyl; optionally substituted cycloalkyl; cycloalkyl-alkyl; aryl; arylalkyl; heteroaryl; heterocycloalkyl; or —COOH and/or —SO3H substituted alkyl;
    • R1, R2, R3, R9, R10 and R11 are as defined in the specification;

      are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds.

    Web www.patentalert.com

    < Platelet adenosine diphosphate receptor antagonists

    < Bifunctionalized polyester material for surface treatment and biomodification

    > Chemokine -7 variants

    > Seventeen amino acid peptide (Peptide P) for treating ischemia and reperfusion injury

    ~ 00258